100 Banger?, page-25

Do you detect any connection between the extracts below taken from recent ASX releases Mal?

From Transcript of Investor Briefing, 25 Feb 2016
“In terms of the therapeutic programs, we have been working very hard, and watch this space. I won't be able to tell you much more on that at the moment, but we do have some major developments coming online in the next few weeks.”

From ASX Release of 8 April 2016
“Cellmid Limited (ASX: CDY) is pleased to advise that in preparation for implementing its clinical development plan it has set up dedicated subsidiaries, Lyramid Limited and Kinera Limited, for the commercialisation of its MK antibody and protein assets, respectively.

Lyramid, a wholly owned subsidiary of Cellmid, has been set up to develop the Company’s large MK antibody portfolio, assessing likely therapeutic indications in fibrotic diseases and cancer. Kinera, also wholly owned by Cellmid, has been formed to commercialise the Company’s MK protein assets in ischemic diseases, with a focus on chronic heart disease.”